Avalo Therapeutics
AVTX | NASDAQ
$7.37
-$0.39 (-5.03%)
At close: Nov 16, 2026, 4:00 PM ET
$7.23
-$0.14 (-1.90%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-5.03%
(1D)No price chart data available for 1D timeframe.
Rating
42.2
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #465/1021 (Top 46%)
Key Statistics
Market Data
Market Cap $426.16M
1D Range
7.26 7.70
52W Range
6.63 22.87
Valuation (TTM)
PE -2.55
PB 0.98
EV/EBITDA -0.36
Valuation (NTM)
Forward PE N/A
Forward PEG 0.04
Price Target $30.00
Cash Flow
FCF Yield -14.4%
SBC Adj. FCF Yield -18.8%
SBC Impact -30.2%
Margins
Gross Margin 71.2%
Operating Margin -161961.0%
FCF Margin -104328.8%
Growth (CAGR)
Revenue 3Y | 5Y -70.3% |
-61.2%
Dil EPS 3Y | 5Y 149.3% |
78.3%
FCF 3Y | 5Y -24.5% |
-14.2%
Returns
ROA -18.4%
ROE -34.2%
ROIC -20.9%
Financial Health
Net Cash
$392.97M
Current Ratio 16.63
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical...
Sector Healthcare
Industry Biotechnology
Employees 33
IPO Date Oct 14, 2015
Website www.avalotx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
7
Consensus
Buy
Price Target
$30.00
Upside
+307.06%
Buy (5)
Hold (2)
Sell (0)
Add to Watchlist
Select watchlists to add or remove AVTX